Juno Therapeutics (JUNO) Reaches $52.89 After 6.00% Down Move; Profile of 12 Analysts Covering Ulta Beauty (ULTA)

November 14, 2017 - By Darrin Black

Among 26 analysts covering Ulta Salon Cosmetics & Fragrance Inc (NASDAQ:ULTA), 12 have Buy rating, 0 Sell and 14 Hold. Therefore 46% are positive. Ulta Salon Cosmetics & Fragrance Inc had 98 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, August 31 by William Blair. The firm has “Buy” rating given on Tuesday, July 11 by Oppenheimer. The stock of Ulta Beauty Inc (NASDAQ:ULTA) has “Hold” rating given on Friday, August 26 by Jefferies. The rating was maintained by JP Morgan with “Overweight” on Monday, November 30. The firm earned “Buy” rating on Monday, July 31 by Cowen & Co. The firm has “Hold” rating by Jefferies given on Wednesday, May 31. Oppenheimer maintained the stock with “Buy” rating in Tuesday, June 20 report. The rating was maintained by RBC Capital Markets on Friday, August 25 with “Hold”. The stock of Ulta Beauty Inc (NASDAQ:ULTA) earned “Strong Buy” rating by Raymond James on Thursday, February 11. The rating was maintained by BMO Capital Markets on Friday, May 26 with “Buy”. See Ulta Beauty Inc (NASDAQ:ULTA) latest ratings:

31/10/2017 Broker: BMO Capital Markets Rating: Hold New Target: $235.0 Maintain
30/10/2017 Broker: RBC Capital Markets Rating: Hold New Target: $250.0 Maintain
23/10/2017 Broker: Robert W. Baird Rating: Buy New Target: $265.0 Maintain
20/10/2017 Broker: Cowen & Co Rating: Buy New Target: $336.0 Maintain
18/10/2017 Broker: PiperJaffray Old Rating: Overweight New Rating: Neutral Downgrade
17/10/2017 Broker: Oppenheimer Rating: Hold New Target: $210.0 Maintain
03/10/2017 Broker: KeyBanc Capital Markets Rating: Buy New Target: $270.0 Maintain
29/09/2017 Broker: Robert W. Baird Rating: Buy New Target: $295.0 Maintain
29/09/2017 Broker: Piper Jaffray Rating: Buy New Target: $260.0 Maintain
28/09/2017 Broker: Cowen & Co Rating: Buy New Target: $336.0 Maintain

The stock of Juno Therapeutics Inc (NASDAQ:JUNO) is a huge mover today! About 847,546 shares traded. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 39.85% since November 14, 2016 and is downtrending. It has underperformed by 56.55% the S&P500.The move comes after 9 months negative chart setup for the $6.04B company. It was reported on Nov, 14 by Barchart.com. We have $49.72 PT which if reached, will make NASDAQ:JUNO worth $362.40 million less.

Investors sentiment increased to 1.05 in 2017 Q2. Its up 0.07, from 0.98 in 2017Q1. It is positive, as 47 investors sold Ulta Beauty Inc shares while 194 reduced holdings. 83 funds opened positions while 169 raised stakes. 53.03 million shares or 1.87% more from 52.05 million shares in 2017Q1 were reported. 135,625 are held by State Common Retirement Fund. State Of New Jersey Common Pension Fund D holds 0.04% or 30,000 shares in its portfolio. M&T Bancshares has 22,557 shares. Advisors Asset Inc reported 0.03% in Ulta Beauty Inc (NASDAQ:ULTA). Apg Asset Mgmt Nv has invested 0.04% in Ulta Beauty Inc (NASDAQ:ULTA). Everence Management Inc invested in 1,400 shares. Putnam Limited Liability Co reported 237,712 shares. Bessemer Grp owns 81 shares for 0% of their portfolio. Dekabank Deutsche Girozentrale has 0.02% invested in Ulta Beauty Inc (NASDAQ:ULTA) for 6,377 shares. Lord Abbett Ltd invested 0.08% in Ulta Beauty Inc (NASDAQ:ULTA). Meiji Yasuda Asset Commerce Ltd holds 2,157 shares. 3,720 are held by Shell Asset Mgmt. Twin Cap Management invested in 0.4% or 23,490 shares. Sit Investment Associates accumulated 0.24% or 33,670 shares. Kentucky Retirement Insurance Trust Fund holds 0.08% or 1,597 shares in its portfolio.

Since June 1, 2017, it had 0 insider buys, and 3 sales for $15.73 million activity. Eck Dennis K also sold $9.39 million worth of Ulta Beauty Inc (NASDAQ:ULTA) shares. Halligan Catherine Ann sold $156,182 worth of Ulta Beauty Inc (NASDAQ:ULTA) on Thursday, June 1. Another trade for 20,000 shares valued at $6.18M was sold by DiRomualdo Robert F.

Ulta Beauty, Inc. is a holding company for the Ulta Beauty group of companies. The company has market cap of $12.30 billion. The Firm is a beauty retailer. It has a 26.65 P/E ratio. The Firm offers cosmetics, fragrance, skin, hair care products and salon services.

About 190,966 shares traded. Ulta Beauty Inc (NASDAQ:ULTA) has risen 41.46% since November 14, 2016 and is uptrending. It has outperformed by 24.76% the S&P500.

Among 16 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 10 have Buy rating, 1 Sell and 5 Hold. Therefore 63% are positive. Juno Therapeutics Inc had 43 analyst reports since July 22, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Wednesday, November 18 by Goldman Sachs. The company was downgraded on Thursday, October 29 by Standpoint Research. Maxim Group maintained Juno Therapeutics Inc (NASDAQ:JUNO) rating on Wednesday, November 23. Maxim Group has “Buy” rating and $34 target. The rating was maintained by Maxim Group on Friday, August 5 with “Buy”. As per Thursday, August 31, the company rating was downgraded by Standpoint Research. The firm has “Outperform” rating by FBR Capital given on Tuesday, August 18. The rating was downgraded by BTIG Research to “Sell” on Thursday, June 8. The stock has “Mkt Perform” rating by FBR Capital on Wednesday, November 23. On Friday, July 8 the stock rating was downgraded by JP Morgan to “Neutral”. The company was maintained on Thursday, November 2 by Leerink Swann.

Investors sentiment increased to 1.33 in 2017 Q2. Its up 0.22, from 1.11 in 2017Q1. It increased, as 21 investors sold Juno Therapeutics Inc shares while 40 reduced holdings. 38 funds opened positions while 43 raised stakes. 53.50 million shares or 13.76% more from 47.03 million shares in 2017Q1 were reported. Leisure Management invested in 8,529 shares or 0.23% of the stock. Jane Street Group Ltd Liability Corporation has 0% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 24,465 shares. Panagora Asset Mngmt Incorporated has invested 0% in Juno Therapeutics Inc (NASDAQ:JUNO). 71,749 are owned by Wells Fargo And Mn. Principal Group has 8,655 shares. Da Davidson & Company holds 0.15% or 219,018 shares. Invesco stated it has 52,994 shares or 0% of all its holdings. Artal Grp stated it has 0.1% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO). Dimensional Fund Advsr L P reported 188,481 shares. Jpmorgan Chase And holds 113,124 shares or 0% of its portfolio. Tci Wealth Advsrs Incorporated reported 27 shares stake. Bnp Paribas Arbitrage Sa reported 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO). Susquehanna Grp Limited Liability Partnership holds 46,474 shares or 0% of its portfolio. Paloma Mgmt owns 11,500 shares. Opus Point Partners Management Limited Co, New York-based fund reported 17,970 shares.

Analysts await Juno Therapeutics Inc (NASDAQ:JUNO) to report earnings on March, 7. They expect $-1.02 earnings per share, down 54.55% or $0.36 from last year’s $-0.66 per share. After $-1.12 actual earnings per share reported by Juno Therapeutics Inc for the previous quarter, Wall Street now forecasts -8.93% EPS growth.

Juno Therapeutics, Inc. is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The company has market cap of $6.04 billion. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. The Company’s product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>